
Background Accurate classification of Müllerian malignancies is essential as treatment increasingly depends on tumor site, histologic subtype, and molecular characteristics. High-grade serous ovarian carcinoma (HGSOC) and uterine serous carcinoma (UPSC) share substantial histopathologic and molecular features, which creates diagnostic challenges when the primary site is unclear. We present a case demonstrating the clinical utility of paired tumor-normal whole-genome sequencing (WGS) in resolving an ambiguous gynecologic primary and identifying hereditary cancer risk. Case Presentation A 57-year-old woman with a history of renal transplantation presented with diffuse peritoneal carcinomatosis, ascites, and markedly elevated CA-125 (1962 U/mL). Ascitic cytology demonstrated high-grade serous carcinoma of Müllerian origin, and she was treated with neoadjuvant carboplatin and paclitaxel for presumed advanced ovarian cancer. Interval cytoreductive surgery demonstrated high-grade serous carcinoma involving the uterus, ovaries, fallopian tubes, and peritoneal surfaces. Although pathology favored an endometrial primary based on serous endometrial intraepithelial carcinoma, the clinical presentation raised concern for a primary peritoneal or tubo-ovarian origin. As part of a translational biorepository study, paired tumor-normal WGS was performed. The CUPPA cancer-of-unknown-primary classifier independently predicted an endometrial primary with 99.6% probability. WGS also identified a pathogenic germline MSH2 variant, establishing Lynch syndrome. Conclusion Paired tumor-normal WGS provided simultaneous diagnostic clarification and hereditary cancer risk assessment in a diagnostically ambiguous Müllerian malignancy. Integration of genomic classification into gynecologic oncology may facilitate more accurate tumor assignment, inform treatment and trial eligibility, and identify patients and families who may benefit from hereditary cancer surveillance and cascade testing.
Objective To compare relative research funding and basic and translational science publications for gynecologic cancers vs. other common cancers, normalized to incidence and mortality rates. Methods SEER data were used to investigate incidence and deaths in the US from 2004 to 2024. Research funding was derived from National Cancer Institute (NCI) data. Google Scholar was utilized to identify oncology and medicine related journals with the highest H-indices. All abstracts on PubMed were reviewed and number of basic and translational science articles manually calculated. Results In 2024, new diagnoses of breast, prostate, lung, and colorectal cancers totaled 313,510, 299,010, 234,580, and 152,810, respectively. Endometrial, ovarian, and cervical cancers accounted for 67,880, 19,680, and 13,820, respectively.NCI funding in 2023 was approximately $542.0 million for breast, $258.6 million for prostate, $435.0 million for lung, and $238.6 million for colorectal cancers, compared to $20.0 million, $132.0 million, and $20.7 million for endometrial, ovarian, and cervical cancers, respectively.Across the highest impact journals from 2004 to 2024, 24,169 basic/translational science publications were found: 8859 (breast), 4161 (prostate), 3537 (lung), 4321 (colorectal), 412 (endometrial), 2231 (ovarian), and 648 (cervical). When adjusted for incidence, ovarian cancer had the highest number of publications, at 220.9 publications per 100,000 cases. When adjusted for funding, endometrial cancer had the highest number of publications, at 23.1 publications per $1 million average annual NCI funding. Conclusion Funding relative to disease burden varies considerably among gynecologic cancers. Endometrial cancer receives the lowest NCI funding of any cancer studied when adjusted by incidence and mortality. Despite this, endometrial cancer produced the most basic and translational science publications per dollar.
Rural patients in the United States face disproportionate gynecologic cancer mortality compared to urban patients, driven by overlapping geographic, socioeconomic, and structural barriers that vary across cancer types and the care continuum. This review synthesizes the literature on rural disparities in cervical, endometrial, and ovarian cancers from prevention through survivorship. Rurality is defined variably across the literature, most commonly using government classification systems such as Rural-Urban Continuum Codes or Rural-Urban Commuting Area codes. Rural women experience lower Human Papillomavirus vaccination rates and reduced uptake of guideline-concordant cervical cancer screening, higher rates of late-stage ovarian cancer diagnosis, and delayed endometrial cancer diagnosis. Even when rural patients access subspecialist care, treatment quality gaps persist, including higher rates of open surgical staging for endometrial cancer and reduced access to brachytherapy for locally advanced cervical cancer. Survival disparities remain even among rural patients treated at tertiary centers with subspecialist involvement, underscoring that geographic access alone is insufficient. Insurance status, health literacy, financial hardship, and limited social support compound these barriers throughout the continuum. Interventions including telehealth, shared care models, community-based navigation, and Medicaid expansion show promise but remain incompletely evaluated in gynecologic oncology. Most existing literature documents disparities without evaluating interventions, and variability in how rurality is defined limits generalizability. Rural women deserve more than documentation of the disparities they face, and closing these gaps will require both coordinated action across clinical, institutional, and policy levels and a stronger evidence base for targeted interventions.